K Number
K133664
Device Name
ENCORE VERSION 16 SOFTWARE FOR GE LUNAR DXA BONE DENSITOMETERS
Date Cleared
2014-05-15

(167 days)

Product Code
Regulation Number
892.1170
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The optional "Complete Pediaric" software option mineral content (BMC), bone nineral density (BMD) and body composition (lean body mass and fat mass) in patients from birth to 20 years of age. The software provides a comparison of measured variables obtained by dual energy x-ray absorpionery to a database of reference values for patients 5-19 years of age. These data can be used for comparative purposes at the sole discretion of the software does not provide a reference population for comparative purposes for patients younger than 5 years of age. Optional Orthopedic software estimates periprosthetic BMD of an orthopedic hip or knee implant (pre- and post-surgery).
Device Description
enCORE software is used on GE Lunar DXA bone densitometers. Release 16 of the enCORE software (enCORE 16 or enCORE 16.xx) includes some feature enhancements. The software will now expand upon its previously cleared pediatric indication (K001812) by providing a "Complete Pediatric" software that can measure the bone mineral content (BMC), bone mineral density (BMD) and body composition (lean body mass and fat mass) in patients from birth to 20 years of age. The software will also provide a comparison of measured variables obtained by dual energy x-ray absorptiometry to a database of reference values for patients 5-19 years of age. The software will also expand its previously cleared orthopedic hip indication (K972517) to include estimates of the BMD of the knee before and after joint implant. The GE Lunar DXA bone densitometers measure the bone mineral density (BMD), lean and fat tissue mass and calculate derivative values of bone mineral content (BMC), area, soft tissue mass, regional soft tissue mass, total soft tissue mass, fat free mass, regional/total soft tissue mass ratio, % fat, region % fat, total body % fat, Android % fat, Gynoid % fat, Android/Gynoid ratio (A/G ratio) and Body Mass Index (BMI).
More Information

No
The document describes standard image processing algorithms and comparisons to reference databases, with no mention of AI or ML techniques.

No
The device measures bone mineral content, density, and body composition for diagnostic and comparative purposes, but it does not treat or cure any medical condition.

Yes

The device measures BMC, BMD, and body composition using dual energy x-ray absorptiometry and compares these measurements to a database of reference values. This process is used to assess the patient's condition, which aligns with the definition of a diagnostic device. The "Intended Use / Indications for Use" section explicitly states that the software provides a comparison of measured variables useful for "comparative purposes," implying diagnostic assessment. Furthermore, it estimates periprosthetic BMD "pre- and post-surgery," indicating its role in evaluating surgical outcomes which is a diagnostic function.

No

The device is described as software that runs on GE Lunar DXA bone densitometers, which are hardware devices that perform dual energy x-ray absorptiometry. The software processes data from this hardware.

Based on the provided text, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD definition: In vitro diagnostics are tests performed on samples such as blood, urine, or tissue that have been taken from the human body. They are used to detect diseases, conditions, or infections.
  • Device function: The description clearly states that this device is a software used on GE Lunar DXA bone densitometers. These densitometers use dual energy x-ray absorptiometry to measure bone mineral density and body composition directly on the patient.
  • No sample analysis: There is no mention of analyzing samples taken from the body. The measurements are performed in vivo (within the living body).

Therefore, the function and method of operation of this device fall outside the scope of an In Vitro Diagnostic.

N/A

Intended Use / Indications for Use

The enCORE version 16 for GE Lunar DXA Bone Densitometers is intended for medical purposes to measure bone density, bone mineral content, and fat and lean tissue content by x-ray transmission measurements through the bone and adjacent tissues.

The optional "Complete Pediaric" software option mineral content (BMC), bone nineral density (BMD) and body composition (lean body mass and fat mass) in patients from birth to 20 years of age. The software provides a comparison of measured variables obtained by dual energy x-ray absorpionery to a database of reference values for patients 5-19 years of age. These data can be used for comparative purposes at the sole discretion of the software does not provide a reference population for comparative purposes for patients younger than 5 years of age.

Optional Orthopedic software estimates periprosthetic BMD of an orthopedic hip or knee implant (pre- and post-surgery).

Product codes

KGI

Device Description

enCORE software is used on GE Lunar DXA bone densitometers. Release 16 of the enCORE software (enCORE 16 or enCORE 16.xx) includes some feature enhancements. The software will now expand upon its previously cleared pediatric indication (K001812) by providing a "Complete Pediatric" software that can measure the bone mineral content (BMC), bone mineral density (BMD) and body composition (lean body mass and fat mass) in patients from birth to 20 years of age. The software will also provide a comparison of measured variables obtained by dual energy x-ray absorptiometry to a database of reference values for patients 5-19 years of age. The software will also expand its previously cleared orthopedic hip indication (K972517) to include estimates of the BMD of the knee before and after joint implant.

The GE Lunar DXA bone densitometers measure the bone mineral density (BMD), lean and fat tissue mass and calculate derivative values of bone mineral content (BMC), area, soft tissue mass, regional soft tissue mass, total soft tissue mass, fat free mass, regional/total soft tissue mass ratio, % fat, region % fat, total body % fat, Android % fat, Gynoid % fat, Android/Gynoid ratio (A/G ratio) and Body Mass Index (BMI).

Mentions image processing

The enCORE version 16 Software Release for the GE Lunar DXA Bone Densitometers employs the same fundamental scientific technology as its predicate device, which is dual-energy x-ray absorptiometry using a PC based image processing algorithm running on a Microsoft Windows operating system.

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

x-ray transmission measurements, dual energy x-ray absorptiometry

Anatomical Site

bone, adjacent tissues, knee, hip

Indicated Patient Age Range

birth to 20 years of age (for specific software features), 5-19 years of age (for reference value comparison)

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The subject of this premarket submission, enCORE version 16 Software Release for the GE Lunar DXA Bone Densitometers, did not require clinical studies to support substantial equivalence. Bench testing was performed to verify the effectiveness of the expanded population range of the "Complete Pediatric" software application from birth to 20 years as well as add the knee as an additional anatomic site for the orthopedic software application.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K001812, K042480, K972517

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.1170 Bone densitometer.

(a)
Identification. A bone densitometer is a device intended for medical purposes to measure bone density and mineral content by x-ray or gamma ray transmission measurements through the bone and adjacent tissues. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.

0

GE Healthcare

510(k) Premarket Notification Submission

Image /page/0/Picture/3 description: The image shows a document with the text 'K133664' at the top, followed by 'page 1 of 3' written in cursive. A circular logo with the letters 'GE' inside is located on the bottom left of the image. The document appears to be the first page of a three-page document, possibly related to a product or service from General Electric (GE).

510(k) Summary

In occordance with 21 CFR 807.92 the following summary of information is provided:

Date:November 27. 2013
Submitter:GE Healthcare (GE Medical Systems Ultrasound & Primary Care
Diagnostics, LLC)
3030 Ohmeda Drive
P.O. Box 7550
Madison, WI 53707
Primary Contact
Person:Chris Paulik
Regulatory Affairs Leader
GE Healthcare (GE Medical Systems Ultrasound & Primary Care
Diagnostics, LLC)
Telephone: (262) 548-2010
Email: Christopher.Paulik@med.ge.com
Secondary Contact
Person:Steven Kachelmeyer
Regulatory Affairs Director
GE Healthcare (GE Medical Systems Ultrasound & Primary Care
Diagnostics, LLC)
Telephone: (262) 548 2432
Email: Steven.Kachelmeyer@med.ge.com
Device Trade Name:Lunar DPX Series: (DPX-MD+, DPX-MD+ Compact , DPX-NT, DPX-NT
Compact, DPX Pro, DPX Bravo, DPX Duo)
Lunar Prodigy Series: (Prodigy, Prodigy Compact, Prodigy Pro, Prodigy
Pro Compact, Prodigy Primo, Prodigy Primo Compact, Prodigy
Advance, Prodigy Advance Compact, Prodigy Forma)
Lunar iDXA Series: (iDXA, iDXA Advance, iDXA Pro, iDXA Forma, Lunar
iDXA)
Common/Usual
Name:Bone Densitometer
Classification
Names:Bone Densitometer (21CFR 892.1170)
Product Code:KGI
Predicate Device(s):Pediatric Reference Data for Prodigy and DPX Bone Densitometers
(K001812)
Infant Whole Body Software Option for QDR Densitometers (K042480)
Expert-XL Orthopedic Hip Acquisition and Analysis Software
(K972517)
Device Description:enCORE software is used on GE Lunar DXA bone densitometers.
Release 16 of the enCORE software (enCORE 16 or enCORE 16.xx)
includes some feature enhancements. The software will now expand
upon its previously cleared pediatric indication (K001812) by
providing a "Complete Pediatric" software that can measure the bone
mineral content (BMC), bone mineral density (BMD) and body
composition (lean body mass and fat mass) in patients from birth to
20 years of age. The software will also provide a comparison of
measured variables obtained by dual energy x-ray absorptiometry to
a database of reference values for patients 5-19 years of age. The
software will also expand its previously cleared orthopedic hip
indication (K972517) to include estimates of the BMD of the knee
before and after joint implant.
The GE Lunar DXA bone densitometers measure the bone mineral
density (BMD), lean and fat tissue mass and calculate derivative
values of bone mineral content (BMC), area, soft tissue mass, regional
soft tissue mass, total soft tissue mass, fat free mass, regional/total
soft tissue mass ratio, % fat, region % fat, total body % fat, Android %
fat, Gynoid % fat, Android/Gynoid ratio (A/G ratio) and Body Mass
Index (BMI).
Intended Use:The enCORE version 16 for GE Lunar DXA Bone Densitometers is
intended for medical purposes to measure bone density, bone
mineral content, and fat and lean tissue content by x-ray
transmission measurements through the bone and adjacent tissues.
Technology:The enCORE version 16 Software Release for the GE Lunar DXA Bone
Densitometers employs the same fundamental scientific technology
as its predicate device, which is dual-energy x-ray absorptiometry
using a PC based image processing algorithm running on a Microsoft
Windows operating system.
The enCORE version 16 Software Release for the GE Lunar DXA Bone
Densitometers has expanded the anatomical sites from the predicate
devices to now also include the knee for orthopedic examinations, pre
and post joint implant, with its optional orthopedic software.
The enCORE version 16 Software Release for the GE Lunar DXA Bone
Densitometers has expanded the patient population from the
predicate devices for the complete pediatric software option to
accommodate those populations from birth to 20 years of age.
The differences discussed in this section do not raise new issues of
safety and effectiveness. Verification and Validation testing
demonstrated that no adverse effects have been introduced by these
differences.
Determination of
Substantial
Equivalence:Summary of Non-Clinical Tests:
The enCORE version 16 Software Release for the GE Lunar DXA Bone
Densitometers and its applications comply with voluntary standards.
The following quality assurance measures were applied to the
development of the system:
■ Risk Analysis
■ Requirements Reviews
■ Design Reviews
■ Testing on unit level (Module verification)
■ Integration testing (System verification)
■ Performance testing (Verification)
■ Safety testing (Verification)
■ Simulated use testing (Validation)
Summary of Clinical Tests:
The subject of this premarket submission, enCORE version 16
Software Release for the GE Lunar DXA Bone Densitometers, did not
require clinical studies to support substantial equivalence. Bench
testing was performed to verify the effectiveness of the expanded
population range of the "Complete Pediatric" software application
from birth to 20 years as well as add the knee as an additional
anatomic site for the orthopedic software application.
Conclusion:The enCORE version 16 Software Release for the GE Lunar DXA Bone
Densitometers expands upon its previously cleared pediatric
indication (K001812) by broadening the patient population from birth
to 20 years of age. The software will also expand its previously
cleared orthopedic hip indication (K972517) to include estimates of
the BMD of the knee before and after joint implant. It does not result
in any new potential safety risks, has the same technological
characteristics, and performs as well as the devices currently on the
market.
After analyzing performance testing on the bench it is the conclusion
of GE Healthcare that the enCORE version 16 Software Release for the
GE Lunar DXA Bone Densitometers e is substantially equivalent to
other marketed devices with similar indications for use and meeting
the same standards.

A-3

1

Image /page/1/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined within a circle. The letters and the circle are black, while the background is white.

GE Healthcare

510(k) Premarket Notification Submission

.

2

Image /page/2/Picture/0 description: The image shows the text "K133664 page 3 of 3" in a handwritten style. The text is arranged in a way that "K133664" is at the top, followed by "page 3 of 3" underneath it. In the bottom left corner of the image, there is a logo of GE, which is a circular emblem with the letters "GE" inside.

.

. .

GE Healthcare

.

. .

:

:

510(k) Premarket Notification Submission

:

:

:

.

3

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

May 15, 2014

GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC % Mr. Chris Paulik Regulatory Affairs Leader 3030 Ohmeda Drive MADISON WI 53718

Re: K133664

Trade/Device Name: enCORE version 16 software for GE Lunar DXA Bone Densitometers Regulation Number: 21 CFR 892.1170 Regulation Name: Bone densitometer Regulatory Class: II Product Code: KGI Dated: April 9, 2014 Received: April 10, 2014

Dear Mr. Paulik:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

4

Page 2 - Mr. Chris Paulik

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/dcfault.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Smh.7)

for

Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

5

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013 See PRA Statement on last page.

510(k) Number (if known) K133664

Device Name

enCORE version 16 for GE Lunar DXA Bone Densitometers

Indications for Use (Describe)

The optional "Complete Pediaric" software option mineral content (BMC), bone nineral density (BMD) and body composition (lean body mass and fat mass) in patients from birth to 20 years of age. The software provides a comparison of measured variables obtained by dual energy x-ray absorpionery to a database of reference values for patients 5-19 years of age. These data can be used for comparative purposes at the sole discretion of the software does not provide a reference population for comparative purposes for patients younger than 5 years of age.

Optional Orthopedic software estimates periprosthetic BMD of an orthopedic hip or knee implant (pre- and post-surgery).

Type of Use (Select one or both, as applicable)

🇿 Prescription Use {Part 21 CFR 801 Subpart D)

] Over-The-Counter Use (21 CFR 801 Subpart C)

Please do not write below this line - continue on a separate page if needed.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Sm)

FORM FDA 3881 (9/13)

Par Publishing Services . BOI : 441-12 Pr